• Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset

Presented by :

Associate Sponsor :

Home » News » Business

Jan 03, 2013, 01.26 PM | Source: Moneycontrol.com

Dr Reddys Labs gains 2% on Finasteride launch in US

Healthcare firm Dr Reddy's Laboratories was the top gainer on the Sensex, rising more than 2 percent on Thursday after the company launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market.

Like this story, share it with millions of investors on M3

Dr Reddys Labs gains 2% on Finasteride launch in US

Healthcare firm Dr Reddy's Laboratories was the top gainer on the Sensex, rising more than 2 percent on Thursday after the company launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market.

Post Your Comments

Share Cancel

Healthcare firm Dr Reddy's Laboratories was the top gainer on the Sensex, rising more than 2 percent on Thursday after the company launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market.

The company's ANDA for Finasteride tablets has been awarded a 180-day period of marketing exclusivity in the US on January 2.

"The Propecia tablets has US sales of approximately USD 136 million MAT for the most recent 12 months ending October 2012, according to IMS Health," the company said in a release.

At 10:36 hours IST, the stock gained 2.13 percent to Rs 1,877 on the Bombay Stock Exchange.

Also Read
Geometric surges on acquisition of 3Cap Technologies
Jet Air rises 6% on impending stake sale deal with Etihad

Dr Reddys Labs stock price

On February 12, 2016, Dr Reddys Laboratories closed at Rs 2846.45, down Rs 40.55, or 1.4 percent. The 52-week high of the share was Rs 4382.95 and the 52-week low was Rs 2750.00.


The company's trailing 12-month (TTM) EPS was at Rs 113.22 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 25.14. The latest book value of the company is Rs 623.31 per share. At current value, the price-to-book value of the company is 4.57.

Related Stories

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Dr Reddys Labs gains 2% on Finasteride launch in US

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login